StudyFinder
A Prospective Low-Interventional Phase 4 Single Arm Study of Ocular Assessments in Patients Treated with Tivdak® in Recurrent or Metastatic Cervical Cancer
Status: Recruiting
The purpose of this study is to learn more about ocular (relating to the eye) side-effects of tisotumab vedotin (brand name: TIVDAK™). A side effect is anything the drug does to your body besides treating your disease. It is approved for women with cervical cancer that has spread through the body or come back during or after chemotherapy. We are doing a study to understand whether there are any ocular side-effects of TIVDAK.
Sex: Female
Age Group: 18 years and over
Inclusion Criteria:
• cervical cancer that has returned (recurrent) or spread to other parts of the body (metastasized) during or after chemotherapy
• doctor has decided that Tivdak® is an option for treatment
• agree to use effective contraception
Exclusion Criteria:
• active eye disease
• women who are breastfeeding, pregnant, or planning to become pregnant
Interventions:
Drug: TIVDAK
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), cervical cancer
Study Contact: Alyssa Pecoraro - pecor029@umn.edu
Principal Investigator: Deanna Teoh
Phase: PHASE4
IRB Number: STUDY00025592
See this study on ClinicalTrials.gov